LONDON, Oct. 22, 2021 /PRNewswire/ -- Hikma
Pharmaceuticals PLC (Hikma), the multinational pharmaceutical
company, announces it has donated 50,000 vials of Naloxone HCl
Injection, USP – a treatment for reversing opioid overdoses – to
members of the Opioid Safety and Naloxone Network (OSNN) Buyers
Club to help ease an acute shortage of the medicine currently
facing non-profit harm-reduction programs in the US.
OSNN is a collective of over 100 harm-reduction programs in the
US who distribute naloxone directly to people who use drugs, their
loved ones, and their communities. Some of their member programs
have been involved in community distribution of naloxone for more
than 20 years. Hikma's donation will be supplied from its
state-of-the-art sterile injectable manufacturing facility in
Cherry Hill, NJ, and is being
provided in collaboration with Hikma Community Health, a new
division of Hikma focused on providing a range of treatment options
in the US for substance use disorder and opioid overdose.
As the US FDA has noted, naloxone is a critical tool for
individuals, families, first responders and communities to help
reduce opioid overdose deaths, and expanding access to all forms of
naloxone is one of the top ways to address the overdose crisis.
"In the middle of a devastating overdose crisis that killed a
record number of our friends, family, colleagues, and community
members, we need to do everything we can to save lives. Naloxone is
our best tool, but unless we take steps to equip harm reduction
organizations, it will be out of reach to the people most likely to
use it and prevent an overdose death," said Maya Doe-Simkins, co-founder of the Opioid
Safety and Naloxone Network Buyers Club. "As we confront a
nationwide shortage of affordable naloxone, we're grateful that
Hikma has come forward to share naloxone with Buyers Club
organizations. These programs and the people who use drugs that
they serve are the backbone of overdose prevention efforts for the
country. We need more leaders and organizations to step up and
support harm reduction in this precarious moment before it's too
late."
"Hikma has played a leading role in addressing shortages of
critical medicines in the US, launching more than 20 medicines into
shortage situations in recent years and receiving an award from the
FDA for our efforts," said Joel
Rosenstack, Chief Commercial Officer, US Injectables, Hikma.
"We are proud to establish this partnership with OSNN, which
furthers our work to resolve drug shortages and aligns with our
Hikma Community Health initiative to provide a range of naloxone,
buprenorphine and methadone medication options to meet the urgent
needs of US patients and communities."
Hikma's naloxone donation continues the company's long-running
commitment to supporting organizations that address health issues
in underserved communities around the world. In 2020, Hikma donated
over $4 million USD in medicines
through its global medicine donation program.
Enquiries
Hikma Pharmaceuticals PLC
Steve
Weiss
|
+1 732 788
8279
|
David
Belian
|
+1 848 254
4875
|
US Communications and
Public Affairs
|
uscommunications@hikma.com
|
About Hikma
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable
S&P and BBB-/stable Fitch)
Hikma helps put better health within reach every day for
millions of people around the world. For more than 40 years, we've
been creating high-quality medicines and making them accessible to
the people who need them. Headquartered in the UK, we are a global
company with a local presence across the
United States (US), the Middle
East and North Africa
(MENA) and Europe, and we use our
unique insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed
to our customers, and the people they care for, and by thinking
creatively and acting practically, we provide them with a broad
range of branded and non-branded generic medicines. Together, our
8,600 colleagues are helping to shape a healthier world that
enriches all our communities. We are a leading licensing partner,
and through our venture capital arm, are helping bring innovative
health technologies to people around the world. For more
information, please visit: www.hikma.com
About Hikma Community Health
Hikma Community Health, a subdivision of Hikma Specialty
USA, is focused on addressing
underserved health burdens that have ripple effects throughout US
communities, including substance use disorder and opioid overdose.
Through Hikma Community Health, Hikma provides a range of naloxone,
buprenorphine and methadone medications options designed to meet
the specific needs of each patient and community.
View original
content:https://www.prnewswire.com/news-releases/hikma-donates-50-000-doses-of-injectable-naloxone-to-help-expand-non-profit-access-to-lifesaving-treatment-for-reversing-opioid-overdoses-301406485.html
SOURCE Hikma Pharmaceuticals USA Inc.